150 related articles for article (PubMed ID: 10996632)
1. Genetically modified tumour vaccines (GMTV) in melanoma clinical trials.
Nawrocki S; Murawa P; Malicki J; Kapcinska M; Gryska K; Izycki D; Kaczmarek A; Laciak M; Czapczyk A; Karczewska A; Rose-John S; Mackiewicz A
Immunol Lett; 2000 Sep; 74(1):81-6. PubMed ID: 10996632
[TBL] [Abstract][Full Text] [Related]
2. [Gene modified tumor vaccines in therapy of malignant melanoma].
Wysocki PJ; Karczewska A; Mackiewicz A
Otolaryngol Pol; 2002; 56(2):147-53. PubMed ID: 12094637
[TBL] [Abstract][Full Text] [Related]
3. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.
Schadendorf D; Paschen A; Sun Y
Immunol Lett; 2000 Sep; 74(1):67-74. PubMed ID: 10996630
[TBL] [Abstract][Full Text] [Related]
4. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
[TBL] [Abstract][Full Text] [Related]
5. Humoral responses to melanoma vaccine, genetically modified with interleukin 6 and soluble interleukin 6 receptor.
Nawrocki S; Łaciak M; Izycki D; Gryska K; Wysocki PJ; Grabarczyk P; Karczewska A; Kaczmarek A; Murawa P; Malicki J; Rose-John S; Mackiewicz A
Adv Exp Med Biol; 2001; 495():411-8. PubMed ID: 11774603
[No Abstract] [Full Text] [Related]
6. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
7. Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer.
Nawrocki S; Wysocki PJ; Mackiewicz A
Expert Opin Biol Ther; 2001 Mar; 1(2):193-204. PubMed ID: 11727529
[TBL] [Abstract][Full Text] [Related]
8. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic vaccines against melanoma and colorectal cancer.
Tartaglia J; Bonnet MC; Berinstein N; Barber B; Klein M; Moingeon P
Vaccine; 2001 Mar; 19(17-19):2571-5. PubMed ID: 11257394
[TBL] [Abstract][Full Text] [Related]
10. Melanoma vaccines.
Yang JC
Cancer J; 2011; 17(5):277-82. PubMed ID: 21952276
[TBL] [Abstract][Full Text] [Related]
11. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
Sondak VK; Sosman JA
Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
[TBL] [Abstract][Full Text] [Related]
12. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of melanoma by GPI-anchored IL-21 tumour vaccine involves down-regulating regulatory T cells in mouse model.
Wang J; Zhao F; Dou J; He XF; Chu L; Cao M; Liu C; Li Y; Gu N
Int J Immunogenet; 2011 Feb; 38(1):21-9. PubMed ID: 20727044
[TBL] [Abstract][Full Text] [Related]
14. Melanoma vaccines: achievements and perspectives.
Brichard VG; Gérard C
Forum (Genova); 2003; 13(2):144-54; quiz 189. PubMed ID: 14732881
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study.
Möller P; Sun Y; Dorbic T; Alijagic S; Makki A; Jurgovsky K; Schroff M; Henz BM; Wittig B; Schadendorf D
Br J Cancer; 1998 Jun; 77(11):1907-16. PubMed ID: 9667667
[TBL] [Abstract][Full Text] [Related]
16. The role of vaccine therapy in the treatment of melanoma.
Lens M
Expert Opin Biol Ther; 2008 Mar; 8(3):315-23. PubMed ID: 18294102
[TBL] [Abstract][Full Text] [Related]
17. Immunological therapy of human tumors by gene-modified cellular vaccines.
Parmiani G
Folia Biol (Praha); 2000; 46(6):207-9. PubMed ID: 11140852
[No Abstract] [Full Text] [Related]
18. Developing recombinant and synthetic vaccines for the treatment of melanoma.
Restifo NP; Rosenberg SA
Curr Opin Oncol; 1999 Jan; 11(1):50-7. PubMed ID: 9914879
[TBL] [Abstract][Full Text] [Related]
19. Tumour cell-based vaccines for the treatment of melanoma.
Hsueh EC
BioDrugs; 2001; 15(11):713-20. PubMed ID: 11707146
[TBL] [Abstract][Full Text] [Related]
20. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
